Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia

NCT07684469 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Coronary Syndrome

Interventions

DRUG: inclisiran
DRUG: SOC

Sponsor

Novartis Pharmaceuticals